Mohamed Raslan¹, Eslam MS¹, Sara AR¹ and Nagwa A Sabri²*

¹Drug Research Centre, Cairo, Egypt
²Department of Clinical Pharmacy, Faculty of Pharmacy- Ain Shams University, Cairo, Egypt

*Corresponding Author: Nagwa A Sabri, Department of Clinical Pharmacy, Faculty of Pharmacy- Ain Shams University, Cairo, Egypt.

Received: March 16, 2022; Published: April 07, 2022

Abstract

Background: The COVID-19 epidemic affects practically every aspect of human activity. The pandemic effect will continue until development of proper vaccine that neutralize different emerging viral variants.

Discussion: Different studies showed an advantage for COVID-19 vaccine third “booster” dose regarding decreased infection rates, hospitalization rates, and morality rates. Furthermore, booster doses showed an enhanced neutralizing antibodies against new emerging Omicron variant. Absolute vaccine effectiveness for BioNTech/Pfizer (BNT162b2) or Moderna (mRNA-1273) booster ranged from 94 to 97 percent. Besides, the 10-fold decrease in infection rate for the boosted with BNT162b2.

Conclusion: It can be concluded that booster doses of COVID-19 vaccine showed beneficial and significant positive effects that we are in need nowadays to overcome the spread of new emerging variants, reducing infection rates, and the burden on health care facilities.

Keywords: COVID-19; Omicron; BioNTech/Pfizer Vaccine; AstraZeneca ChAdOx1

References

1. Hoffmann M., et al. “SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor”. Cell 181 (2020): 271-280.
2. Wu Z and McGoogan JM. “Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention”. JAMA 323 (2020): 1239-1242.
3. Sabri NA., et al. “Genetic variants of COVID-19 and vaccination. Is there a Correlation?” Open Journal of Proteomics and Genomics 1 (2022): 001-005.
4. Sara AR., et al. “Potential effects of genetic polymorphism on anesthesia use for COVID-19 infected patients at intensive care unit”. Scientific Journal of Genetics and Gene Therapy 1 (2022): 001-008.
5. Munro Alasdair P., et al. “Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial”. The Lancet10318 (2020): 2258-2276.
6. Liu X., et al. “Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial”. Lancet 398 (2021): 856-869.
7. Hulme WJ., et al. “Comparative effectiveness of ChAdOx1 versus BNT162b2 COVID-19 vaccines in health and social care workers in England: a cohort study using Open SAFELY”. medRxiv (2021).
8. Pouwels KB., et al. “Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK”. Nature Medicine (2021).
9. Kamar N., et al. “Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients”. The New England Journal of Medicine 385 (2021): 661-662.
10. Krause Philip R., et al. “Considerations in boosting COVID-19 vaccine immune responses”. Lancet (London, England)10308 (2021): 1377-1380.
11. Garcia-Beltran WF., et al. “mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant”. Cell (2022): S0092-8674 (21)01496-3.
12. Gargano JW., et al. “Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices-United States, June 2021”. Morbidity and Mortality Weekly Report (MMWR) 70 (2021): 977-982.
13. Munro APS., et al. “Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial”. Lancet 10318 (2021): 2258-2276.
14. Andrews N., et al. “Effectiveness of COVID-19 booster vaccines against covid-19 related symptoms, hospitalisation and death in England”. Nature Medicine (2022).
15. Barda N., et al. “Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study”. Lancet10316 (2021): 2093-2100.
16. Bar-On YM., et al. “Protection against Covid-19 by BNT162b2 Booster across Age Groups”. The New England Journal of Medicine 26 (2021): 2421-2430.
17. Wald A. “Booster Vaccination to Reduce SARS-CoV-2 Transmission and Infection”. JAMA 4 (2022): 327-328.
18. Nagwa A Sabri., et al. “Virtual and on Site Vaccination Clinics of COVID-19. Will it be Applicable?". Acta Scientific Pharmaceutical Sciences 1 (2022): 141-144.

Citation

Citation: Nagwa A Sabri., et al. “The Significance of COVID-19 Vaccine Booster Dose. A Comparative Review". Acta Scientific Pharmaceutical Sciences 6.5 (2022): 03-07.

Copyright

Copyright: © 2022 Nagwa A Sabri., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.